Drugs / REGN1154
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01540539 | Mar 2012 → Jan 2013 | — | Regeneron Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGN1154 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01540539 ↗ |
| Route | Intravenous | “intravenous (IV) and subcutaneous (SC) administration of REGN1154” NCT01540539 ↗ |
| Route | Subcutaneous | “intravenous (IV) and subcutaneous (SC) administration of REGN1154” NCT01540539 ↗ |